STOCK TITAN

CASI Pharmaceuticals, Inc. Ordinary Shares - CASI STOCK NEWS

Welcome to our dedicated news page for CASI Pharmaceuticals Ordinary Shares (Ticker: CASI), a resource for investors and traders seeking the latest updates and insights on CASI Pharmaceuticals Ordinary Shares.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CASI Pharmaceuticals Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CASI Pharmaceuticals Ordinary Shares's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.22%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
partnership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.8%
Tags
CASI Pharmaceuticals, Inc. Ordinary Shares

Nasdaq:CASI

CASI Rankings

CASI Stock Data

32.03M
5.44M
47.13%
2.07%
0.61%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Rockville

About CASI

casi pharmaceuticals, inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in china, the united states, and internationally. the company's product pipeline includes evomela, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. its product pipeline also comprise cnct19, an autologous cd19 car-t investigative product for the treatment of patients with b-cell acute lymphoblastic leukemia (b-all) and b-cell non-hodgkin lymphoma; cid-103, an anti-cd38 monoclonal antibody being for the treatment of patients with multiple myeloma; zevalin, a cd20-directed radiotherapeutic antibody, to treat patients with nhl; and thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. in addition, the company of